329 related articles for article (PubMed ID: 29352503)
1. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
3. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
4. The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
Anand JP; Boyer BT; Mosberg HI; Jutkiewicz EM
Psychopharmacology (Berl); 2016 Jul; 233(13):2479-87. PubMed ID: 27117141
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.
Lowery JJ; Raymond TJ; Giuvelis D; Bidlack JM; Polt R; Bilsky EJ
J Pharmacol Exp Ther; 2011 Mar; 336(3):767-78. PubMed ID: 21118955
[TBL] [Abstract][Full Text] [Related]
6. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
8. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
9. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
[TBL] [Abstract][Full Text] [Related]
10. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
11. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
12. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
13. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
Mada S; Gerak LR; Soyer A; Maguire DR; Hu Z; Minervini V; Cunningham CW; France CP
Psychopharmacology (Berl); 2020 Dec; 237(12):3591-3602. PubMed ID: 32820390
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-
Yadlapalli JSK; Bommagani SB; Mahelona RD; Wan A; Gannon BM; Penthala NR; Dobretsov M; Crooks PA; Fantegrossi WE
Pharmacol Res Perspect; 2018 Jul; 6(4):e00403. PubMed ID: 29930811
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
17. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
18. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
20. Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence.
Wilson LL; Harris HM; Eans SO; Brice-Tutt AC; Cirino TJ; Stacy HM; Simons CA; León F; Sharma A; Boyer EW; Avery BA; McLaughlin JP; McCurdy CR
Drug Alcohol Depend; 2020 Nov; 216():108310. PubMed ID: 33017752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]